Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Metadata listed "Alterity Therapeutics," but the filing text identifies Prana Biotechnology Limited).
Filing Type: Form 6-K (Report of Foreign Private Issuer).
Reporting Period: Half-year ended 31 December 2017.
Business Overview: Prana is a development-stage medical biotechnology company focused on research into Parkinsonian movement disorders, Alzheimer's disease, Huntington's disease, and other neurodegenerative disorders. The company operates in a single segment and has established a U.S. operation in San Francisco for clinical development.
Key Financial Metrics
| Metric | 31 Dec 2017 (A$) | 31 Dec 2016 (A$) |
|---|---|---|
| Revenue from Ordinary Activities | 117,168 | 72,883 |
| Other Income (R&D Tax Incentive) | 1,360,238 | 1,830,734 |
| Total Loss for the Period | (3,617,439) | (3,651,845) |
| Net Tangible Assets per Share | 3.77 cents | 5.16 cents |
| Cash and Cash Equivalents | 19,911,187 | 28,341,761 |
| Net Cash Outflow from Operating Activities | (1,172,663) | (620,953) |
| Total Liabilities | 1,815,580 | N/A (Prior period not directly comparable in table) |
Note: The company reported no debt in the form of borrowings; liabilities consist primarily of trade payables and provisions.
Material Changes vs. Prior Period
- Revenue Growth: Revenue from ordinary activities increased by 60.8% to A$117,168, driven primarily by interest income.
- Loss Reduction: The net loss decreased slightly by 0.9% to A$3,617,439.
- R&D Expenses: Research and development expenses decreased significantly to A$2,286,286 from A$3,832,414 in the prior period.
- Foreign Exchange: The company recorded a foreign exchange loss of A$610,939, compared to a gain of A$496,019 in the prior period.
- Cash Position: Cash reserves decreased by approximately A$1.8 million year-over-year, largely due to operating outflows and foreign exchange effects.
Outlook, Risks, and Management Commentary
Operational Updates
- PBT434 (Movement Disorder): Continuing evaluation in mouse models of atypical Parkinsonism. The candidate blocks alpha-synuclein aggregation.
- PBT2 (Huntington's Disease): Management is reviewing options for additional non-clinical studies, FDA-permitted dosing levels, or alternative therapeutic applications.
- Pipeline: New candidates have emerged from the Translational Biology Program using new chemical scaffolds.
Liquidity and Going Concern
Directors believe the company has sufficient cash reserves to meet forecast outflows for at least 12 months. Key liquidity factors include:
- ATM Facility: An "at market" facility allows for the raising of up to US$50 million via American Depositary Receipts (ADRs).
- Options: 30 million unlisted options are on issue; full exercise would yield A$2.49 million (not guaranteed).
- Tax Incentives: A receivable of A$1,360,238 from the Australian Tax Office for R&D incentives is expected within 12 months.
- Contingency: The company retains the ability to scale down operations and prioritize R&D programs if funding is insufficient.
Risks
The primary risk is the inherent uncertainty of cash flow forecasts related to R&D expenditure. The company is in a development stage and expects to utilize cash until research activities become marketable.
Investor Verification Checklist
- Verify the status and timeline of the PBT434 and PBT2 clinical development programs.
- Confirm the expected timing of the A$1.36 million R&D tax incentive refund from the Australian Tax Office.
- Monitor the utilization of the US$50 million ATM facility for future capital raises.
- Review the burn rate relative to the current cash balance of ~A$19.9 million to assess runway.
- Check for any updates on the new pipeline candidates mentioned in the Translational Biology Program.